Novo Nordisk is investing 1.5 billion Danish kroner ($225 million) in a new 7,500 square meeter facility in Kalundborg, Denmark. The facility will produce active pharmaceutical ingredients for NovoSeven (coagulation Factor VIIa [recombinant]) and future products for treating hemophilia.

The company broke ground on the new facility on May 4, 2015, and the facility is expected to be approved and fully operational in 2020. The Kalundborg production site is Novo Nordisk’s largest with a total area of 1 million square meters. Novo Nordisk has made ongoing investments in the site since 1999.

The new investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people. “The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees,” said Henrik Wulff, executive vice president, product supply, Novo Nordisk, in a company statement.

Source: Novo Nordisk